A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer

Trial Profile

A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms VELVET
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.
    • 01 Oct 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top